Literature DB >> 16377724

Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin.

Maxime Gualtieri, Philippe Villain-Guillot, Jaqueline Latouche, Jean-Paul Leonetti, Lionel Bastide.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16377724      PMCID： PMC1346796          DOI： 10.1128/AAC.50.1.401-402.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Lipiarmycin: an antibiotic inhibiting nucleic acid polymerases.

Authors:  M Talpaert; F Campagnari; L Clerici
Journal:  Biochem Biophys Res Commun       Date:  1975-03-03       Impact factor: 3.575

2.  Structural basis of transcription initiation: an RNA polymerase holoenzyme-DNA complex.

Authors:  Katsuhiko S Murakami; Shoko Masuda; Elizabeth A Campbell; Oriana Muzzin; Seth A Darst
Journal:  Science       Date:  2002-05-17       Impact factor: 47.728

3.  In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.

Authors:  Sydney M Finegold; Denise Molitoris; Marja-Liisa Vaisanen; Yuli Song; Chengxu Liu; Mauricio Bolaños
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis.

Authors:  M S Osburne; A L Sonenshein
Journal:  J Virol       Date:  1980-03       Impact factor: 5.103

5.  Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination.

Authors:  J E Hochlowski; S J Swanson; L M Ranfranz; D N Whittern; A M Buko; J B McAlpine
Journal:  J Antibiot (Tokyo)       Date:  1987-05       Impact factor: 2.649

6.  In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.

Authors:  R N Swanson; D J Hardy; N L Shipkowitz; C W Hanson; N C Ramer; P B Fernandes; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

7.  Lipiarmycin-resistant ribonucleic acid polymerase mutants of Bacillus subtilis.

Authors:  A L Sonenshein; H B Alexander; D M Rothstein; S H Fisher
Journal:  J Bacteriol       Date:  1977-10       Impact factor: 3.490
  7 in total
  11 in total

1.  In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.

Authors:  Douglas J Biedenbach; James E Ross; Shannon D Putnam; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

2.  The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site.

Authors:  Audrey Tupin; Maxime Gualtieri; Jean-Paul Leonetti; Konstantin Brodolin
Journal:  EMBO J       Date:  2010-06-18       Impact factor: 11.598

3.  In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.

Authors:  James A Karlowsky; Nancy M Laing; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

Review 4.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  A Mutation in the Bacillus subtilis rsbU Gene That Limits RNA Synthesis during Sporulation.

Authors:  David M Rothstein; David Lazinski; Marcia S Osburne; Abraham L Sonenshein
Journal:  J Bacteriol       Date:  2017-06-27       Impact factor: 3.490

6.  Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea.

Authors:  Yoav Golan; Lauren Epstein
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

Review 7.  Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.

Authors:  Jennifer A Leeds
Journal:  Cold Spring Harb Perspect Med       Date:  2016-02-01       Impact factor: 6.915

8.  In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm.

Authors:  Philippe Villain-Guillot; Maxime Gualtieri; Lionel Bastide; Jean-Paul Leonetti
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

Review 9.  New target for inhibition of bacterial RNA polymerase: 'switch region'.

Authors:  Aashish Srivastava; Meliza Talaue; Shuang Liu; David Degen; Richard Y Ebright; Elena Sineva; Anirban Chakraborty; Sergey Y Druzhinin; Sujoy Chatterjee; Jayanta Mukhopadhyay; Yon W Ebright; Alex Zozula; Juan Shen; Sonali Sengupta; Rui Rong Niedfeldt; Cai Xin; Takushi Kaneko; Herbert Irschik; Rolf Jansen; Stefano Donadio; Nancy Connell; Richard H Ebright
Journal:  Curr Opin Microbiol       Date:  2011-08-19       Impact factor: 7.934

Review 10.  Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.

Authors:  George G Zhanel; Andrew J Walkty; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Nov-Dec       Impact factor: 2.471
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.